Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.

Jun LS, Millican RL, Hawkins ED, Konkol DL, Showalter AD, Christe ME, Michael MD, Sloop KW.

Diabetes. 2015 Mar;64(3):819-27. doi: 10.2337/db14-1052. Epub 2014 Oct 6.

PMID:
25288673
2.

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.

West GM, Willard FS, Sloop KW, Showalter AD, Pascal BD, Griffin PR.

PLoS One. 2014 Sep 2;9(9):e105683. doi: 10.1371/journal.pone.0105683. eCollection 2014.

3.

Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells.

Zhang M, Robitaille M, Showalter AD, Huang X, Liu Y, Bhattacharjee A, Willard FS, Han J, Froese S, Wei L, Gaisano HY, Angers S, Sloop KW, Dai FF, Wheeler MB.

Mol Cell Proteomics. 2014 Nov;13(11):3049-62. doi: 10.1074/mcp.M114.040196. Epub 2014 Jul 20.

PMID:
25044020
4.

A novel humanized GLP-1 receptor model enables both affinity purification and Cre-LoxP deletion of the receptor.

Jun LS, Showalter AD, Ali N, Dai F, Ma W, Coskun T, Ficorilli JV, Wheeler MB, Michael MD, Sloop KW.

PLoS One. 2014 Apr 2;9(4):e93746. doi: 10.1371/journal.pone.0093746. eCollection 2014.

5.

The identification of novel proteins that interact with the GLP-1 receptor and restrain its activity.

Huang X, Dai FF, Gaisano G, Giglou K, Han J, Zhang M, Kittanakom S, Wong V, Wei L, Showalter AD, Sloop KW, Stagljar I, Wheeler MB.

Mol Endocrinol. 2013 Sep;27(9):1550-63. doi: 10.1210/me.2013-1047. Epub 2013 Jul 17.

PMID:
23864651
6.

Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.

Willard FS, Wootten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, Bokvist K, Alsina-Fernandez J, Furness SG, Christopoulos A, Sexton PM, Sloop KW.

Mol Pharmacol. 2012 Dec;82(6):1066-73. doi: 10.1124/mol.112.080432. Epub 2012 Aug 28.

7.

Allosteric modulation of endogenous metabolites as an avenue for drug discovery.

Wootten D, Savage EE, Valant C, May LT, Sloop KW, Ficorilli J, Showalter AD, Willard FS, Christopoulos A, Sexton PM.

Mol Pharmacol. 2012 Aug;82(2):281-90. doi: 10.1124/mol.112.079319. Epub 2012 May 10.

8.

Model of pediatric pituitary hormone deficiency separates the endocrine and neural functions of the LHX3 transcription factor in vivo.

Colvin SC, Malik RE, Showalter AD, Sloop KW, Rhodes SJ.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):173-8. doi: 10.1073/pnas.1009501108. Epub 2010 Dec 13.

9.

Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.

Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, Farb TB, Cao JX, Cox AL, Michael MD, Gutierrez Sanfeliciano SM, Tebbe MJ, Coghlan MJ.

Diabetes. 2010 Dec;59(12):3099-107. doi: 10.2337/db10-0689. Epub 2010 Sep 7.

10.

Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.

Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, Monia BP.

Amyloid. 2010 Jun;17(2):43-9. doi: 10.3109/13506129.2010.483121.

PMID:
20462362
11.

Specific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease.

Sloop KW, Showalter AD, Cox AL, Cao JX, Siesky AM, Zhang HY, Irizarry AR, Murray SF, Booten SL, Finger EA, McKay RA, Monia BP, Bhanot S, Michael MD.

J Biol Chem. 2007 Jun 29;282(26):19113-21. Epub 2007 May 3.

12.

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.

Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW.

Muscle Nerve. 2006 May;33(5):609-18.

PMID:
16421881
13.

Conserved amino acid sequences confer nuclear localization upon the Prophet of Pit-1 pituitary transcription factor protein.

Guy JC, Hunter CS, Showalter AD, Smith TP, Charoonpatrapong K, Sloop KW, Bidwell JP, Rhodes SJ.

Gene. 2004 Jul 21;336(2):263-73.

PMID:
15246537
14.

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, Jacobs SJ, Moyers JS, Owens RA, Showalter AD, Brenner MB, Raap A, Gromada J, Berridge BR, Monteith DK, Porksen N, McKay RA, Monia BP, Bhanot S, Watts LM, Michael MD.

J Clin Invest. 2004 Jun;113(11):1571-81.

15.

Cloning and analysis of axolotl ISL2 and LHX2 LIM-homeodomain transcription factors.

Showalter AD, Yaden BC, Chernoff EA, Rhodes SJ.

Genesis. 2004 Mar;38(3):110-21.

PMID:
15048808
16.

Genetic defects in the development and function of the anterior pituitary gland.

Cushman LJ, Showalter AD, Rhodes SJ.

Ann Med. 2002;34(3):179-91. Review.

PMID:
12173688
17.
18.

Identification of porcine Lhx3 and SF1 as candidate genes for QTL affecting growth and reproduction traits in swine.

Smith TP, Showalter AD, Sloop KW, Rohrer GA, Fahrenkrug SC, Meier BC, Rhodes SJ.

Anim Genet. 2001 Dec;32(6):344-50.

PMID:
11736804
19.

Molecular analysis of LHX3 and PROP-1 in pituitary hormone deficiency patients with posterior pituitary ectopia.

Sloop KW, Walvoord EC, Showalter AD, Pescovitz OH, Rhodes SJ.

J Clin Endocrinol Metab. 2000 Aug;85(8):2701-8.

PMID:
10946868
20.

Analysis of the human LHX3 neuroendocrine transcription factor gene and mapping to the subtelomeric region of chromosome 9.

Sloop KW, Showalter AD, Von Kap-Herr C, Pettenati MJ, Rhodes SJ.

Gene. 2000 Mar 21;245(2):237-43.

PMID:
10717474
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk